Polycythemia - secondary
Also known as: Hypertension, High blood pressure, Elevated, Secondary
Methodology & AI Transparency ⓘ
Polycythemia - secondary Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Polycythemia - secondary (also termed Hypertension or High blood pressure) is an ICD-10-CM indexed diagnosis (D75.1) within Anemia, Clotting & Blood Disorders.
- 2 Real-world patient consensus: Synonyms for Polycythemia - secondary (D75.1): Hypertension, High blood pressure, Elevated (Blood & Anemia).
- 3 Typical cash cost range: Clinicians assessing Polycythemia - secondary focus on chronic inflammatory hepcidin in Polycythemia - secondary (D75.1: iron sequestration) and targeted history.
- 4 Top reported side effects / signs: Key Blood & Anemia biomarkers for Polycythemia - secondary (D75.1): Hemoglobin, Hematocrit & in Polycythemia - secondary (D75.1: MCV) & Serum Ferritin & in Polycythemia - secondary (D75.1: Transferrin Saturation) (Ferritin 50–150 ng/mL; TSAT 20%–45% (D75.1)).
Ask our AI Specialists anything about Polycythemia - secondary
What Is Polycythemia - secondary?
Polycythemia - secondary (also termed Hypertension or High blood pressure) is an ICD-10-CM indexed diagnosis (D75.1) within Anemia, Clotting & Blood Disorders. Clinical evaluation centers on complete blood count in Polycythemia - secondary (D75.1: with peripheral smear) alongside serial Hemoglobin, Hematocrit & in Polycythemia - secondary (D75.1: MCV) tracking (Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D75.1)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Polycythemia - secondary (D75.1) alters blood & anemia homeostasis through chronic inflammatory hepcidin in Polycythemia - secondary (D75.1: iron sequestration); clinical remission targets Serum Ferritin & in Polycythemia - secondary (D75.1: Transferrin Saturation) within Ferritin 50–150 ng/mL; TSAT 20%–45% (D75.1).
Common Symptoms & Clinical Signs
- • Presentation of Polycythemia - secondary (D75.1): exertional fatigue, reduced in Polycythemia - secondary (D75.1: stamina, pale conjunctiva,)
- • Secondary Polycythemia - secondary clinical sign: restless legs, ice in Polycythemia - secondary (D75.1: craving)
- • Symptom flares in Polycythemia - secondary correlating with Hemoglobin, Hematocrit & in Polycythemia - secondary (D75.1: MCV) deviation outside Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D75.1)
- • Functional blood & anemia impact requiring complete blood count in Polycythemia - secondary (D75.1: with peripheral smear) evaluation (D75.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Polycythemia - secondary Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D75.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin, Hematocrit & in Polycythemia - secondary (D75.1: MCV) | Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D75.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Polycythemia - secondary (D75.1: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D75.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Polycythemia - secondary (D75.1: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D75.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Polycythemia - secondary
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Medroxyprogesterone Acetate Depo-Subq Provera, Provera • RxCUI 1000114 | Progestin | 94% | $50.1220 | $ 7.23 /mo |
| Norethindrone Acetate Gallifrey, Aygestin • RxCUI 1000405 | Progestin | 85% | $0.2895 | $ 8.48 /mo |
| Mifepristone Korlym • RxCUI 1245262 | Progestin Antagonist | 84% | $1.2200 | $ 57.91 /mo |
| Korlym (Mifepristone) Korlym • RxCUI RXN-B76346073 | Progestin Antagonist | 94% | $1.4100 | $ 110.02 /mo |
| Anagrelide Agrylin • RxCUI 597850 | Platelet-reducing Agent | 83% | $0.7112 | $ 24.30 /mo |
| Calcitriol Vectical, Rocaltrol • RxCUI 308867 | Vitamin D3 Analog | 82% | $0.1607 | $ 7.20 /mo |
| Doxercalciferol Hectorol • RxCUI 282609 | Vitamin D2 Analog | 76% | $2.6600 | $ 207.22 /mo |
| Dextromethorphan Hydrobromide and Quinidine Sulfate Nuedexta • RxCUI 1040054 | Antiarrhythmic | 74% | $25.8727 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Polycythemia - secondary)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A: What a 219-Participant Study Found CPLE is a potential therapeutic intervention to improve CIT faster and to a greater extent than placebo in this phase III randomized trial without any safety concerns. JCO global oncology • 2026-03-15 • Phase III Randomized Trial | N = 219 | 88/100 | PMID 41812092 ↗ |
| Can This Approach Help? Inside the Latest Research on Comparing Rates of Polycythemia in Hypogonadal Men Using Nasal Testosterone Gel Men with hypogonadism who use intranasal testosterone are less likely to develop polycythemia than men using intramuscular testosterone cypionate. European urology focus • 2023-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 36109330 ↗ |
Polycythemia - secondary Patient Community & “People Like Me” Threads
Filter Polycythemia - secondary community threads and patient logs by age, biological sex, dosage, and treatment duration.